Growth Transformation of B Cells by Epstein-Barr Virus Requires IMPDH2 Induction and Nucleolar Hypertrophy
暂无分享,去创建一个
T. Kanda | H. Saya | T. Murata | Y. Yanagi | Y. Iwatani | H. Kimura | K. Matsuoka | A. Sugimoto | Yoshitaka Sato | E. Sugihara | Yohei Narita | Takahiro Watanabe | Tomihiko Ide | T. Onouchi | Yusuke Okuno | Seiyo Mabuchi | Hiroyuki Nobusue | Masaya Hirayama
[1] T. Murata,et al. Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation , 2021, Viruses.
[2] M. Uddin,et al. A STING inhibitor suppresses EBV‐induced B cell transformation and lymphomagenesis , 2021, Cancer science.
[3] H. Trottier,et al. Risk factors for post‐transplant Epstein‐Barr virus events in pediatric recipients of hematopoietic stem cell transplants , 2021, Pediatric transplantation.
[4] T. Kanda,et al. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. , 2021, Virology.
[5] Y. Okuno,et al. Role of Epstein–Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma , 2021, Cancers.
[6] Bo Zhao,et al. Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival , 2021, bioRxiv.
[7] B. Sugden,et al. Epstein–Barr Virus: How Its Lytic Phase Contributes to Oncogenesis , 2020, Microorganisms.
[8] N. Koonrungsesomboon,et al. Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent. , 2020, European journal of pharmacology.
[9] A. Sasaki,et al. GTP Metabolic Reprogramming by IMPDH2: Unlocking Cancer Cells' Fueling Mechanism. , 2020, Journal of biochemistry.
[10] H. Katoh,et al. Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2 , 2020, Microbiology and immunology.
[11] John G Doench,et al. DNA Methylation Enzymes and PRC1 Restrict B-cell Epstein-Barr Virus Oncoprotein Expression , 2020, Nature Microbiology.
[12] John G Doench,et al. MYC Controls the Epstein-Barr Virus Lytic Switch. , 2020, Molecular cell.
[13] Y. Okuno,et al. Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection , 2020, bioRxiv.
[14] Yuan Tian,et al. The expression and prognostic role of IMPDH2 in ovarian cancer. , 2020, Annals of diagnostic pathology.
[15] Atique U. Ahmed,et al. De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma , 2020, bioRxiv.
[16] J. C. de la Torre,et al. Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses , 2020, Journal of Virology.
[17] J. Gall. The human nucleolus organizer regions , 2019, Genes & development.
[18] Masahiro Yoshida,et al. Antitumor activity of cyclin‐dependent kinase inhibitor alsterpaullone in Epstein‐Barr virus‐associated lymphoproliferative disorders , 2019, Cancer science.
[19] Eric P. Smith,et al. Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story , 2019, Cancers.
[20] M. Weekes,et al. Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival , 2019, PLoS pathogens.
[21] A. Rickinson,et al. The Global Landscape of EBV-Associated Tumors , 2019, Front. Oncol..
[22] R. Deberardinis,et al. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma , 2019, Nature Cell Biology.
[23] W. Hammerschmidt,et al. The first days in the life of naïve human B-lymphocytes infected with Epstein-Barr virus , 2019, bioRxiv.
[24] Mingxiang Teng,et al. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes , 2019, Journal of Virology.
[25] M. Morton,et al. A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature , 2019, Oncotarget.
[26] A. Scialdone,et al. Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection , 2018, Proceedings of the National Academy of Sciences.
[27] P. Wieczorek,et al. Inosine monophosphate dehydrogenase 2 as a marker of aggressive and advanced prostate cancer , 2018, Central European journal of urology.
[28] R. Deberardinis,et al. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. , 2018, Cell metabolism.
[29] Jiaxing Zhang,et al. Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma. , 2018, American journal of cancer research.
[30] Bo Zhao,et al. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300 , 2018, Journal of Virology.
[31] E. Kieff,et al. The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. , 2017, Cell host & microbe.
[32] R. Scott. Epstein-Barr virus: a master epigenetic manipulator. , 2017, Current opinion in virology.
[33] M. West. Chromatin reorganisation in Epstein-Barr virus-infected cells and its role in cancer development. , 2017, Current opinion in virology.
[34] M. Koopmans,et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication , 2017, Antimicrobial Agents and Chemotherapy.
[35] Deepali Kumar,et al. Clinical and virologic outcomes in high‐risk adult Epstein‐Barr virus mismatched organ transplant recipients , 2017, Clinical transplantation.
[36] John G Doench,et al. CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. , 2017, Cell host & microbe.
[37] Jiaxing Zhang,et al. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma , 2017, Scientific Reports.
[38] E. Kieff,et al. Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation , 2016, Proceedings of the National Academy of Sciences.
[39] M. Koopmans,et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. , 2016, Antiviral research.
[40] M. Oren,et al. The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. , 2016, Seminars in cancer biology.
[41] J. Rathmell,et al. Metabolic stress is a barrier to Epstein–Barr virus-mediated B-cell immortalization , 2016, Proceedings of the National Academy of Sciences.
[42] P. Burger,et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage , 2015, Oncotarget.
[43] M. Luftig,et al. To Be or Not IIb: A Multi-Step Process for Epstein-Barr Virus Latency Establishment and Consequences for B Cell Tumorigenesis , 2015, PLoS pathogens.
[44] E. Kieff,et al. Epstein-Barr virus oncoprotein super-enhancers control B cell growth. , 2015, Cell host & microbe.
[45] E. Kieff,et al. Epstein–Barr virus latent genes , 2015, Experimental & Molecular Medicine.
[46] Y.G. Li,et al. IMPDH2 mediate radioresistance and chemoresistance in osteosarcoma cells. , 2014, European review for medical and pharmacological sciences.
[47] R. Pearson,et al. Targeting the nucleolus for cancer intervention. , 2014, Biochimica et biophysica acta.
[48] D. Xia,et al. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer , 2014, Clinical and Translational Oncology.
[49] A. Feinberg,et al. Large-scale hypomethylated blocks associated with Epstein-Barr virus–induced B-cell immortalization , 2014, Genome research.
[50] Fatima Al-Shahrour,et al. The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion , 2013, Genome Biology.
[51] M. Fraga,et al. The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion , 2013, Genome Biology.
[52] J. Kwekkeboom,et al. Mycophenolic acid augments interferon‐stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo , 2012, Hepatology.
[53] D. Abramowicz,et al. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[54] I. Hutchinson,et al. Association of Immunosuppressive Maintenance Regimens With Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients , 2012, Transplantation.
[55] M. Klinger,et al. Malignancy after renal transplantation in the new era of immunosuppression. , 2011, Annals of transplantation.
[56] Robert E. White,et al. An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells , 2010, Cell host & microbe.
[57] J. Fellenberg,et al. Overexpression of Inosine 5′-Monophosphate Dehydrogenase Type II Mediates Chemoresistance to Human Osteosarcoma Cells , 2010, PloS one.
[58] W. Hammerschmidt,et al. Micro RNAs of Epstein-Barr Virus Promote Cell Cycle Progression and Prevent Apoptosis of Primary Human B Cells , 2010, PLoS pathogens.
[59] T. Kanda,et al. Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation. , 2009, The Journal of general virology.
[60] B. Chaigne-Delalande,et al. The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal1 , 2008, The Journal of Immunology.
[61] A. Makhlough,et al. Posttransplant lymphoproliferative disorders in kidney transplant recipients: an Iranian multicenter experience. , 2008, Iranian journal of kidney diseases.
[62] L. Montanaro,et al. Nucleolus, ribosomes, and cancer. , 2008, The American journal of pathology.
[63] K. Zeller,et al. Global Regulation of Nucleotide Biosynthetic Genes by c-Myc , 2008, PloS one.
[64] D. Zhuang,et al. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells , 2008, Cell cycle.
[65] L. Young,et al. EBV gene expression and regulation , 2007 .
[66] R. Moss‐Morris,et al. Epstein-Barr virus infection , 2007 .
[67] F. Boisvert,et al. The multifunctional nucleolus , 2007, Nature Reviews Molecular Cell Biology.
[68] Elliott Kieff,et al. RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[69] A. Walker,et al. Posttransplant Lymphoproliferative Disorder among Renal Transplant Patients in Relation to the Use of Mycophenolate Mofetil , 2005, Transplantation.
[70] W. Hammerschmidt,et al. Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis , 2005, PLoS biology.
[71] S. Peñuelas,et al. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells , 2005, The FEBS journal.
[72] A. Allison. Mechanisms of action of mycophenolate mofetil , 2005, Lupus.
[73] J. Shaughnessy,et al. Phase I Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil (Cellcept) in Advanced Multiple Myeloma Patients , 2004, Clinical Cancer Research.
[74] M. O. Moraes,et al. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. , 2004, Transplantation proceedings.
[75] E. De Clercq,et al. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice , 2003, BMC Microbiology.
[76] S. Hamilton-Dutoit,et al. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? , 2003, Transplantation.
[77] M. Diamond,et al. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. , 2002, Virology.
[78] D. Stablein,et al. Mycophenolate, tacrolimus and post‐transplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study , 2002, Pediatric transplantation.
[79] D. Margolis,et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. , 2002, Antiviral research.
[80] L. Strobl,et al. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. , 2001, Seminars in cancer biology.
[81] M. Melamed,et al. Morphometry of nucleoli and expression of nucleolin analyzed by laser scanning cytometry in mitogenically stimulated lymphocytes. , 2001, Cytometry.
[82] J. Lerut,et al. USE OF MYCOPHENOLATE MOFETIL AS RESCUE THERAPY AFTER PEDIATRIC LIVER TRANSPLANTATION , 2001, Transplantation.
[83] S. Hamilton-Dutoit,et al. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. , 1999, Transplantation.
[84] E. De Clercq,et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro , 1999, Journal of viral hepatitis.
[85] B. Kempkes,et al. The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.
[86] L. Shaw,et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. , 1998, Transplantation.
[87] L. Shaw,et al. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. , 1995, Clinical chemistry.
[88] A. Allison,et al. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. , 1994, Transplantation proceedings.
[89] E. Kieff,et al. Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes , 1994, Antimicrobial Agents and Chemotherapy.
[90] Liang Zhou,et al. Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer , 2014, Medical Oncology.
[91] M. Parida,et al. Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. , 2011, Antiviral research.
[92] R. Hetzer,et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.